Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Natera to Seek FDA Clearance of Oncology Assay as NIPT Business Continues to Grow

Natera to Seek FDA Clearance of Oncology Assay as NIPT Business Continues to Grow

May 09, 2018
|
Monica Heger
Premium

SAN FRANCISCO (GenomeWeb) – Natera said it is on track for an end of the year or early 2019 launch of a clinical version of its circulating tumor DNA assay Signatera and that it planned to eventually submit it to both the US Food and Drug Administration and the Centers for Medicare and Medicaid Services.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

And a Third

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

More Details Wanted

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

Glimpses of Viral Origins

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

PLOS Papers on Plasmodium Falciparum Populations, Scabies Molecular Diagnostics, More

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.

Mar
09
Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

Sponsored by
Fabric Genomics

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams. 

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
16
Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Sponsored by
Bio-Rad

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community. 

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

What's Popular?

In Sequencing

  1. TGen-Led Team Spots Pediatric, Pancreatic Cancer From cfDNA Fragments in Urine

    Premium

  2. New Method Provides NGS-Based Readout of Glycan Levels in Single Cells

    Premium

  3. Personalis to Broaden Liquid Biopsy Footprint With Minimal Residual Disease Testing

    Premium

  4. Adaptive Biotechnologies Touts New Era of T Cell-Based Dx With T-Detect COVID Launch

    Premium

  5. Personal Genome Diagnostics to Build Commercial Infrastructure, Drive Partnerships With New Funding

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.